The exposure of acute myeloid leukemia (AML) cells to BIM-2 resulted in a remarkable antitumor activity as a consequence of the drug-mediated down-regulation of both MYC and BCL2, two oncogenes the over-expression of which is associated with the development of AML [71]. Here, BCL2L11 is linked to acute myeloid leukemia.